| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our robust menu of biomarker testing assesses liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on component tests for six biomarkers to assess the liver for nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH)-FibroTest, which evaluates 10 biomarkers to assess liver condition; and direct alcohol biomarker testing, which assesses the blood for alcohol use.
80M–100M
80M–100M Americans have NAFLD1
25%
25% of patients with NAFLD WILL progress to NASH2
11%
11% of NASH patients progress to cirrhosis3
Metabolic liver disease Test menu
FibroTest-ActiTest assesses the liver for fibrosis and inflammation using two diagnostic scores based on component testing of six biomarkers. It is the most reliable biomarker test available, applies to the largest number of patients (98%),4 and outperforms other testing at all stages of fibrosis.5
Key testing
Advantages
Highlights
Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
Using a simple blood sample, our nonalcoholic steatohepatitis FibroTest combines 10 standard biomarkers into five scores to provide a complete assessment of the liver condition and the five main causes of liver disease, including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.
Key testing
Advantages
Diagnosing individuals with alcoholic liver disease, which encompasses a spectrum of liver injury, often requires a history of significant alcohol intake, clinical evidence of liver disease, and supporting laboratory testing.7 Our menu of direct ethanol biomarker testing accurately assesses alcohol use and includes direct biomarker testing, which enables detection of even small amounts of ethanol eliminated via non-oxidative pathways into ethyl glucuronide (EtG), ethyl sulfate (EtS), and phosphatidylethanol (PEth).8
Benefits of biomarker testing include improved analysis of the specific role alcohol plays in an individual’s health; clarity on the actual amounts of recent consumption, which, combined with questionnaires, can support initiating clinical interventions; and verification and monitoring of ethanol abstinence in liver transplant candidates/patients.
Key testing
Highlights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.